Page last updated: 2024-12-07

rmi 12330a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

RMI 12330A: adenyl cyclase inhibitor in rat liver; RN given refers to (cis)-isomer; NM refers to HCl, (cis)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID123893
SCHEMBL ID896428
SCHEMBL ID20794257
MeSH IDM0063827

Synonyms (9)

Synonym
mdl 12330a
rmi 12330 a
82985-31-7
azacyclotridec-1-en-2-amine, n-(2-phenylcyclopentyl)-, cis-
rmi 12330a
n-[(1r,2r)-2-phenylcyclopentyl]-1-azacyclotridecen-2-amine
n-(cis-2-phenylcyclopentyl)azacyclotridecan-2-imine hydrochloride
SCHEMBL896428
SCHEMBL20794257

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The drug acted with a similar dose-response curve upon intact as well as detergent-dispersed cyclase preparations."( RMI 12330 A, an inhibitor of adenylate cyclase in rat liver.
Berthelot, P; Guellaen, G; Hanoune, J; Mahu, JL; Mavier, P, 1977
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (141)

TimeframeStudies, This Drug (%)All Drugs %
pre-199035 (24.82)18.7374
1990's22 (15.60)18.2507
2000's53 (37.59)29.6817
2010's31 (21.99)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 9.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index9.52 (24.57)
Research Supply Index4.96 (2.92)
Research Growth Index4.48 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (9.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other141 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]